Home › NCT05359562
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
Harnessing Hormonal Variation to Probe Neural Mechanisms and Optimize CBT Outcomes for OCD
Who can join
Ages 18 to 45 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnosis of OCD; 2. Male and female subjects aged between 18- 45; 3. Women must be menstruating and regularly cycling 4. Ability to tolerate a treatment-free period; 5. No psychotropic medication in the past 12 weeks 6. At entry, at least moderate severity OCD 7. Willingness and ability to give written informed consent after full explanation of study procedures. Exclusion Criteria: 1. Use of birth control (oral contraception or IUD) that affects the menstrual cycle, or menopause. 2. Pregnancy. Women of childbearing potential will be required to sign a statement indicating their intention to avoid pregnancy during the study. 3. Neurologic or medical condition that would prevent safe participation in the full study protocol. 4. Any contradiction to magnetic resonance imaging (e.g., metallic implants or devices). 5. Comorbid psychiatric conditions that significantly elevate the risks associated with study participation or confound results. 6. Patients with prominent suicidal ideation or with a recent suicide attempt. 7. Current psychotherapy
About the study
Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.
What is being tested
- Exposure & Response Prevention (EX/RP) (behavioral)
Sponsor: University of Pennsylvania · Participants: 120 · Started: Jun 15, 2022
Contact the study team
- Bryanna Mackey · Phone: 2157463344
- Sara Rose Shannon, BS, MS · Phone: 6467748082
Official record on ClinicalTrials.gov — NCT05359562
Locations in the U.S.
| New York | New York State Psychiatric Institute, New York |
| Pennsylvania | University of Pennsylvania, Philadelphia |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.